For type 2 diabetes mellitus. ANDA 206145, held by Alkem Labs Ltd. Metformin Hydrochloride.
As of Nov 16, 2026, ANDA 206145 (Metformin Hydrochloride), held by Alkem Labs Ltd, was first approved by FDA on Oct 22, 2018, with 1 approved supplement and 0 published complete response letters.
Metformin hydrochloride tablets is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 22, 2018 | Original application | Approved | None posted |
| Metformin Hydrochloride500MG · tablet, extended release;oral | Metformin Hydrochloride | Rx |
| Metformin Hydrochloride750MG · tablet, extended release;oral | Metformin Hydrochloride | Rx |
| Aug 11, 2026 | Supplement 15Labeling · Standard review | Approved | None posted |
| Oct 22, 2018 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters